术后心理干预对卵巢癌患者负面情绪及生活质量的影响

目的 分析术后心理干预对卵巢癌患者负面情绪及生活质量的影响.方法 选择在本院接受手术治疗的卵巢癌患者作为研究对象,随机分为接受常规术后护理的对照组和接受针对性术后心理干预的观察组,比较两组患者的负面情绪、应激水平及生活质量评分差异.结果 (1)观察组患者接受针对性术后心理干预后的焦虑及抑郁评分均明显低于对照组患者(P＜0.05);(2)观察组患者接受术后心理干预后的GIU、E、NE、COI水平均明显低于对照组患者(P＜0.05);(3)观察组患者接受针对性术后心理干预后的各项生活质量评分值均明显低于对照组患者(P＜0.05).结论 卵巢癌患者术后进行针对性心理干预可以有效缓解患者不良情绪状态,缓解全身应激水平,最终提升术后生活质量,具有积极的临床意义.     

归芍地黄丸中山茱萸的定性定量方法研究

摘 要 目的： 建立归芍地黄丸中山茱萸的定性和定量测定方法。方法: 采用TLC对归芍地黄丸中山茱萸进行定性鉴别,并采用HPLC测定山茱萸中莫诺苷、 马钱苷的含量。结果: TLC色谱斑点清晰,分离度好,专属性强;莫诺苷对照品在0.010～2.620 μg范围内线性关系良好（r=0.999 9）,平均回收率为102.75％,RSD为1.40％（n=6）。马钱苷对照品在0.009～2.170 μg范围内线性关系良好（r=0.999 9）,平均回收率为103.59%,RSD为1.10%（n=6）。结论:本方法准确、简单、可行,重复性好,可有效控制该制剂中山茱萸的质量。     

药用植物蓝刺头的研究进展

摘 要 蓝刺头（Echinops latifolius Tausch）为菊科蓝刺头属植物,其干燥根作为中药禹州漏芦用,其干燥花絮作为蒙药蓝刺头用。本文对近几年来中药禹州漏芦和蒙药蓝刺头的研究成果进行了整理,并从化学成分、工艺研究、质量控制和药理作用四个方面对两种药材进行了比较和综述,以期为药用植物蓝刺头的进一步开发和利用提供科学依据。     

加校正因子的自身对照法测定淫羊藿饮片中6种成分含量

摘 要 目的： 采用加校正因子的自身对照法测定淫羊藿饮片中6种成分含量。方法: Agilent ZORBAX Eclipse XDB-C₁₈(150 mm×4.6 mm,5 μm)色谱柱,流动相为乙腈 水梯度洗脱,检测波长268 nm,柱温30℃。通过加入自身内标物色谱峰峰面积增加值建立校正因子,用相对保留时间和光谱对照法确定其他成分位置,采用HPLC色谱法对其他成分进行定量分析。结果:淫羊藿饮片中朝藿定A、朝藿定A1、朝藿定B、朝藿定C、宝藿苷Ｉ相对于淫羊藿苷的保留时间分别为0.750,0.810,0.865,0.939,1.651;校正因子分别为0.998 6,0.998 7,0.998 8,0.989 4,0.985 6。结论: 加校正因子的自身对照法可以用于相同类型化学环境成分的定量测定,该方法简便、快捷,适合中药多成分的定量分析。     

UPLC法测定奈韦拉平的含量及有关物质

目的：改进奈韦拉平的含量和有关物质测定方法 方法：采用 Acquity UPLC TSS T3 C18（2.1mm×50mm,1.8μm）,流动相为10mmol? L-1磷酸二氢铵溶液（pH5.0）-乙腈（80∶20）,流量为0.7ml?min-1,检测波长为220nm。结果：奈韦拉平在0.16～0.96mg? ml-1的范围内线性关系良好（r＝0.999,n＝6）, 平均回收率为99.6%,RSD＝2.0%（n＝9）。结论：本方法快速、简便、准确,专属性强。     

右旋糖酐在注射用醋酸卡泊芬净无菌检查中的应用

目的：通过无菌方法学验证试验,建立注射用醋酸卡泊芬净的无菌检查法。方法：样品分别用0.9%无菌氯化钠溶液溶解,采用薄膜过滤法处理,每膜分别用0.9%无菌氯化钠溶液和右旋糖酐40葡萄糖注射液冲洗若干次,并在培养基中加入右旋糖酐1g,以白色念珠菌为阳性对照菌。结果：各验证菌株均能够正常生长,方法可行。结论：通过添加外源的右旋糖酐,使真菌通过利用外源的肽聚糖用于自身细胞壁的合成,从而消除了醋酸卡泊芬净的抑菌作用,建立了抗真菌药物注射用醋酸卡泊芬净的无菌检查法。     

气囊辅助内镜治疗小肠息肉的临床价值研究

目的：探讨应用气囊辅助内镜（ BAE）治疗小肠息肉的可行性、安全性及临床价值。方法回顾性总结2006年8月至2014年7月对199例小肠息肉患者行BAE检查及内镜下息肉切除治疗情况,评价其可行性、安全性及小肠息肉内镜治疗的临床价值。结果199例小肠息肉患者共接受558例次BAE诊治术,摘除小肠息肉共3391枚,其中直径5～10 mm 801枚（23．62％）,11～30 mm 1887枚（55．65％）,31～50 mm 563枚（16．60％）,＞50 mm 140枚（4．13％）,最大者约为7 cm ×10 cm。发生21例次（3．76％）手术相关并发症,包括15例息肉残根出血和6例肠穿孔。结论 BAE是一种安全有效的小肠息肉治疗方法,对大多数小肠息肉患者,可替代外科手术而作为首选治疗方法,具有较好的临床应用价值及发展前景。     

Efficacy of Acetazolamide for the Prophylaxis of Acute Mountain Sickness: A Systematic Review,Meta-Analysis and Trial Sequential Analysis of Randomized Clinical Trials

BackgroundAcute mountain sickness (AMS) is a benign and self-limiting syndrome but can progress to life-threatening conditions if leave untreated. This study aimed to assess the efficacy of acetazolamide for the prophylaxis of AMS and disclose potential factors that affect the treatment effect of acetazolamide.Materials and MethodsRandomized controlled trials comparing the use of acetazolamide versus placebo for the prevention of AMS were included. The incidence of AMS was the primary endpoint. Meta-regression analysis was conducted to explore potential factors associated with acetazolamide efficacy. Trial sequential analysis (TSA) was conducted to estimate the statistical power of the available data.ResultsA total of 22 trials were included. Acetazolamide at 125, 250, and 375 mg/ twice daily (bid) significantly reduced incidence of AMS compared to placebo. TAS indicated that the current evidence was adequate confirming the efficacy of acetazolamide at 125, 250, and 375 mg/bid in lowering incidence of AMS. There was no evidence of an association between efficacy and dose of acetazolamide, timing at start of acetazolamide treatment, mode of ascent, AMS assessment score, timing of AMS assessment, baseline altitude, and endpoint altitude.ConclusionAcetazolamide is effective prophylaxis for the prevention of AMS in doses of 125, 250, and 375 mg/bid. Future investigations should focus on personal characteristics, disclosing the correlation between acetazolamide efficacy and body mass, height, degree of prior acclimatization, individual inborn susceptibility, and history of AMS.     

Acupoint catgut embedding therapy for functional constipation: A protocol for systematic review and meta-analysis

Background:This review will assess current evidence related to the effectiveness and safety of acupoint catgut embedding therapy for functional constipation (FC) and provide efficacy assessments for clinical applications.Methods:We will search the following databases for relevant trials: PubMed, EMBASE OVID, Cumulative Index of Nursing and Allied Health Literature, OVID MEDLINE, Web of Science, the Cochrane Central Register of Controlled Trials, Cochrane library, and Scopus. We will also search the following Chinese databases for trials published in the Chinese literature: China National Knowledge Infrastructure Database (CNKI), Chinese Scientific Journals Database, Wan Fang Database, Chinese Biomedicine and other resources from inception to December 2020. Only randomized controlled trials comparing acupoint catgut embedding versus acupuncture or sham acupuncture or placebo or other therapies will be included. The outcomes involved mean spontaneous bowel movements, complete spontaneous bowel movements, the Bristol Stool Form Scale, the Cleveland Clinic Score, Patient Assessment of Constipation symptom and so on. The risk of bias assessment and quality of evidence for outcomes will be appraised using the Cochrane Risk of Bias Tool and the Grading of Recommendations, Assessment, Development and Evaluation guidelines. RevMan 5.3 software will be employed for the meta-analysis.Results:This work will compare and arrange the comparative efficacy of acupoint catgut embedding with different treatments for FC by summarizing the current evidences.Conclusion:The results of this meta-analysis may help doctors determine the best treatments for patients to manage FC.Ethics and dissemination:This is a protocol with no patient recruitment and personal information collection, approval by the ethics committee is not required.OSF Registration number:DOI 10.17605/OSF.IO/XTKE2.